Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Intima Bioscience

Main focus: Next generation cell therapies for solid tumours

Company stage: Clinical

Diseases: Multiple solid tumours

Genome editing tool: CRISPR-Cas9

Funding stage: Private

Location: New York, USA

Website: https://www.intimabioscience.com/

Intima Bioscience is a clinical-stage gene and cell therapy company focused on developing cures for solid cancers. The company develops tumour-infiltrating lymphocytes (TILs) in which the novel cytokine checkpoint CISH is disrupted using CRISPR. The company is currently testing its lead programme in multiple solid tumours in a Phase 1/2 clinical trial.

Intima Bioscience, Inc.

Press Releases

Related News and Updates

Job Opportunities

Clinical Trials

Pre-clinical Trials

Stocks and Markets

Diseases

Webinar

Your Latest CMN News

Tune Therapeutics to Initiate Clinical Trial of...

CMN Clinical

Nov. 21, 2024

Tune Therapeutics has received clinical trial application approval from the New Zealand Medicines and Medical Devices Safety Authority to initiate a...

CRISPR Unlocks Sweeter Tomatoes Without Yield Loss

Carbon

Nov. 19, 2024

Chinese scientists have achieved a significant advance in tomato agriculture by leveraging CRISPR–Cas9 to enhance sweetness without yield loss. The...

Tackling Antibiotic-Resistant Staphylococcus...

CMN Interview

Nov. 18, 2024

Researchers in Japan have used phagemids for the delivery of CRISPR components to bacteriophage, selectively killing multi-drug resistant bacteria in...

CMN Weekly (15 November 2024) - Your Weekly CRISPR...

CMN Weekly

Nov. 15, 2024

Some of the best links we picked up around the internet

CRISPR Screens Identify Vital lncRNAs

CMN Briefs

Nov. 12, 2024

American researchers have used transcriptome-wide CRISPR-Cas13 screens in multiple human cell lines to identify 46 universally essential and more than...

CMN Weekly (8 November 2024) - Your Weekly CRISPR...